Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

AI Market Cap Crosses $26 Billion as Ruvi AI (RUVI) Unveils Major Platform Upgrade and New Proprietary Technology

May 30, 2026

World Vape Day 2026: One Switch – Everyone Wins

May 30, 2026

Immigration lawyers say automation is partly driving a massive Federal Court backlog

May 30, 2026

JELLY TIDE [URGENT REPORT 2026]: The Shocking Rise of JellyTide Gummies—What Consumers Need to Know About the Viral Wellness Trend

May 30, 2026

Yanik Guillemette — “Canada Slips Into Recession While Ottawa Bills $200,000 for In-Flight Luxury Meals”

May 30, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Sword Health Appoints Bruce Broussard, Former CEO of Humana, as Board Advisor
Press Release

Sword Health Appoints Bruce Broussard, Former CEO of Humana, as Board Advisor

By News RoomFebruary 6, 20253 Mins Read
Sword Health Appoints Bruce Broussard, Former CEO of Humana, as Board Advisor
Share
Facebook Twitter LinkedIn Pinterest Email

New York, Feb. 06, 2025 (GLOBE NEWSWIRE) — Sword Health, an AI health company making world-class, life-changing care accessible anytime, anywhere, today announced the appointment of Bruce Broussard, former CEO of Humana, as a board advisor. Broussard’s extensive experience in healthcare innovation and leadership further strengthens Sword Health’s mission to free the world from pain. 

“Bruce’s visionary leadership and unwavering commitment to advancing healthcare accessibility and outcomes make him an invaluable addition to Sword,” said Virgílio Bento, Founder and CEO of Sword Health. “As we continue to grow globally and transform care delivery, his expertise will be pivotal in shaping our strategy and amplifying our impact.”

Broussard served as CEO of Humana from 2011 to 2024, where he led the company through transformative growth, expanding its focus on integrated care delivery and innovative health services. Under his leadership, Humana became a leader in value-based care and significantly enhanced its capabilities in digital health and consumer engagement. Broussard’s experience will help guide Sword’s strategic initiatives and growth in delivering high-quality care to millions worldwide.

“I’m truly thrilled to join Sword Health as a Board Advisor and contribute to Sword’s mission of transforming digital healthcare” said Broussard. “What drew me to Sword is its innovative approach—blending AI-powered care models with expert clinical guidance to set a new standard for accessible, effective care delivery. It’s truly a game changer for healthcare”

Sword is at the forefront of the AI revolution in healthcare, combining the power of proprietary AI with real, human clinical expertise to deliver world-class care. The company has achieved industry-leading outcomes, helping employers, health plans, and individuals reduce pain, avoid unnecessary surgeries, save millions on health-related costs and improve overall quality of life.

With the addition of Broussard’s expertise, Sword is poised to accelerate its efforts to expand access to its innovative care model and reinforce its position as the leader in AI Care.

About Sword Health
As a global leader in AI Care, Sword Health makes world-class care available anytime, anywhere, by combining human clinicians and AI. Starting with physical pain, then pelvic health, and now a full platform of solutions, Sword is available through more than 25,000 employers, health plans, and public sector organizations, saving those clients an average of $3 in healthcare costs for every $1 invested in Sword. To date, the company has saved its clients more than $650 million in unnecessary healthcare costs. With a mission to free two billion people from pain, the company has raised more than $300 million from leading venture firms, including Khosla Ventures and General Catalyst. It was most recently valued at $3 billion and won Fast Company’s World Changing Ideas Award in the health services category. Learn more at www.swordhealth.com. 

  • Sword Health Appoints Bruce Broussard, Former CEO of Humana, as Board Advisor

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

AI Market Cap Crosses $26 Billion as Ruvi AI (RUVI) Unveils Major Platform Upgrade and New Proprietary Technology

World Vape Day 2026: One Switch – Everyone Wins

JELLY TIDE [URGENT REPORT 2026]: The Shocking Rise of JellyTide Gummies—What Consumers Need to Know About the Viral Wellness Trend

Yanik Guillemette — “Canada Slips Into Recession While Ottawa Bills $200,000 for In-Flight Luxury Meals”

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Atlanta Based Health Center celebrates 50 Years of Service

Taklimakan Rally 2026: GWM TANK Dominates the Unforgiving Desert

12B SPORTS Named Main Sponsor of VR46 Racing Team for the 2026 MotoGP Season

Enabled Talent Hosts Cross-Party MPP Breakfast Reception at Queen’s Park During National AccessAbility Week

Editors Picks

World Vape Day 2026: One Switch – Everyone Wins

May 30, 2026

Immigration lawyers say automation is partly driving a massive Federal Court backlog

May 30, 2026

JELLY TIDE [URGENT REPORT 2026]: The Shocking Rise of JellyTide Gummies—What Consumers Need to Know About the Viral Wellness Trend

May 30, 2026

Yanik Guillemette — “Canada Slips Into Recession While Ottawa Bills $200,000 for In-Flight Luxury Meals”

May 30, 2026

Latest News

007 First Light is the James Bond game we’ve been waiting for

May 30, 2026

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

May 30, 2026

Atlanta Based Health Center celebrates 50 Years of Service

May 30, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version